menu
    • menu

    List of Certificates of Suitability (CEPs) for Active Pharmaceutical Ingredients (APIs) issued to UQUIFA by EDQM. Original Data: EDQM Database

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    UQUIFASpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    C/ Mallorca 262, 3rd floor, Barcelona 08008
    Telephone
    Telephone
    +34 934 674 810
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://uquifa.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/uquifa/
    Twitter
    Twitter
    https://twitter.com/uquifa?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI Worldwide, Milan

    CPhI Worldwide, Milan

    Not Confirmed

    envelop Contact Supplier

    CPhI Worldwide, Milan

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”

    “We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”

    This week, SpeakPharma interviews Mike Riley, CEO of Veranova, a leading contract development and manufacturing organization (CDMO) confidently mastering complex APIs as it marks its second year as an independent company. Riley discusses Veranova’s key achievements, including a US$ 30 million investment in their Devens, Massachusetts (US) site to expand capabilities in antibody-drug conjugates (ADCs) and highly potent APIs (HPAPIs), and how it is navigating the increasing complexity of molecules. 🔑 HIGHLIGHTS// Veranova’s key achievements / navigating the increasing complexity of molecules Veranova is celebrating its second year as a stand-alone company. Can you share Veranova’s key milestones and achievements in its first two years? We have achieved incredible milestones over the last two years, thanks to the dedication and hard work of our team. Our first 12 months focused on establishing ourselves as an independent CDMO by building on the 50 years of expertise that we brought with us. In addition, we expanded our capabilities and applied a more agile approach available to us as a company singularly focused on life sciences. This has allowed us to move into our second year with clear and strategic goals for generating growth in our sites, people, capabilities, and offerings. Since being appointed as CEO in May 2023, I’ve had the pleasure of witnessing some exciting growth milestones of my own. Most recently, we announced an estimated US$ 30 million investment in our Devens, Massachusetts, site. This expansion will allow us to build upon existing development and manufacturing capabilities in ADCs and HPAPIs that will address the growing demand for strong US-based capacity in these key drug modalities. We also appointed our Advisory Board, thereby bolstering Veranova’s in-house expertise. Made up of four distinguished leaders in pharma and biopharma – including Dr. Carolyn Bertozzi, the 2022 Nobel Laureate in Chemistry – the Board has provided thought-leadership, guidance and expertise as we develop and execute our strategic growth and ideas. We were also proud to be recognized as one of the Society of Chemical Manufacturers and Affiliates’ 12 companies for industry-leading safety programs in 2023 and as a part of the Medicine Maker’s Power List in 2024. 🔑 HIGHLIGHTS// US$ 30 million investment in our Devens, Massachusetts, site / appointed our Advisory Board Molecules are becoming increasingly complex. Can you elaborate on how Veranova’s current capabilities are strategically designed to address this trend in the coming years? The pharmaceutical pipeline is witnessing an increasing number of complex and highly potent molecules. This trend is driven by the demand for more targeted, patient-centric therapeutics and the focus on innovative modalities such as ADCs and other bioconjugates. At Veranova, our expertise, world-class facilities, and scientific excellence enable us to provide our customers with the clarity and solutions needed to manage this development and manufacturing complexity and ultimately deliver the required treatments to customers and patients. Our people are key to this approach. We have an expert team ready to collaborate with customers at any point, from early development through large-scale commercial production. Our services include world-leading crystallization development, process development, and specialized manufacturing expertise for complex synthetic molecules, including those requiring chromatography capabilities. In many cases, we can provide all these under one roof. Our service offering to our customers is also based on the foundational element of strong quality and compliance systems. We operate multiple facilities approved by the US FDA, UK’s MHRA and other regulatory authorities and are continually focused on ways to strengthen our global quality management system. Looking ahead, we are focused on continually investing in our facilities and team to meet growing complexity, as evidenced by our recent announcement of new investment in our Devens site. This investment signals our commitment to providing state-of-the-art capacity and capabilities to enable these next-generation therapies to reach patients. It is a key milestone as we advance Veranova’s broader growth strategy. 🔑 HIGHLIGHTS// provide our customers with clarity and solutions / world-leading crystallization development / expertise for complex synthetic molecules / strong quality and compliance systems How is Veranova approaching the challenge of designing and manufacturing effective linker molecules for ADCs? As a leader in complex linker-payload synthesis, Veranova is committed to unlocking the life-changing potential of ADCs without letting their complexities slow down the development of much-needed cancer therapies. ADCs are intricate, multi-component molecules that require extensive expertise and agile collaboration to overcome unique development challenges. With over a decade of experience in ADC linker-payload systems, we have developed the ability to anticipate challenges and avoid common pitfalls. The ADC linker-payload components are complex structures that are difficult to crystallize and require specialized high-potent handling. Veranova’s differentiated combination of world-leading crystallization development capabilities, complex synthesis experience, chromatography expertise and high-potent-handling experience put us in a unique position to solve these challenges for customers and speed their products to the clinic. We prioritize getting it right the first time, minimizing change orders and ensuring high-quality results. We have developed a robust phase-appropriate strategy that is backed by state-of-the-art analytical equipment and regulatory procedures to ensure our partners can rapidly progress their ADC projects from pre-clinical to commercialization. 🔑 HIGHLIGHTS// unlocking the life-changing potential of ADCs / ensuring our partners can rapidly progress their ADC projects Can you specify how Veranova is using artificial intelligence (AI) to optimize manufacturing processes that can reduce costs and environmental footprint as well as speed up development? In May 2024, Veranova announced a partnership with Phorum.AI to leverage AI to optimize pharmaceutical manufacturing processes. This collaboration aims to enable the rapid development of processes that can drive efficiency and reduce costs while maximizing environmental sustainability. Our goal is to combine Veranova’s extensive empirical manufacturing dataset of owned APIs and drug master files with Phorum.AI’s computational chemistry engine in order to create a more powerful process-development tool for the benefit of Veranova’s and Phorum’s customers. At Veranova, we are constantly looking to employ innovative technologies and approaches to improve efficiency, accelerate time to market and reduce environmental footprint. We have the means to work with a variety of partners who have unique project requirements, without sacrificing time to market.  🔑 HIGHLIGHTS// partnership with Phorum.AI / create a more powerful process-development tool / improve efficiency, accelerate time to market and reduce environmental footprint

    Impressions: 1852

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/we-re-unlocking-life-changing-potential-in-complex-molecules-without-sacrificing-time-to-market

    #SpeakPharma With Veranova
    10 Sep 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans

    BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans

    Over the last two years, there has been a significant surge in layoffs by pharmaceutical and biotech companies. The trend spilled over to 2024. Data compiled by PharmaCompass indicates that between January and early-September, around 150 companies had implemented layoffs. Bristol Myers Squibb (BMS) tops the list of companies that downsized, with a staggering 2,284 job cuts. Bayer stood second at 1,816 retrenchments, followed by Takeda Pharmaceuticals at 1,155. Johnson & Johnson’s spin-off Kenvue is slashing over 1,000 jobs this year, while Roche subsidiary Genentech is cutting 529 positions, and Novartis is going ahead with its multi-year restructuring, and cutting another 770 jobs. One of the primary drivers of layoffs has been the need for companies to streamline operations and reduce costs. Many firms have faced financial pressures due to reasons such as declining revenues, increased competition, and the high costs associated with drug development. The current wave of layoffs has encompassed geographies – from traditional pharma strongholds like New Jersey, biotech hubs in Massachusetts and California, to Europe (particularly Germany and Switzerland). This is not to suggest that job cuts are a norm. Certain segments have been experiencing substantial growth and job creation. This includes companies like Eli Lilly and Novo Nordisk that have experienced remarkable growth due to the efficacy of their glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs that treats type 2 diabetes and obesity.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available) BMS cuts 2,284 jobs to meet cost targets, Bayer hands pink slips to 1,816 employees Several large drugmakers have announced job cuts this year in order to meet their cost cutting goals, or as part of their restructuring exercise. BMS’ revenue had declined from US$ 46.2 billion in 2022 to US$ 45 billion in 2023. The financial pressure has compelled it to cut 2,284 jobs so far in this year, a move that sent shockwaves through the industry. Overall, BMS hopes to save approximately US$ 1.5 billion in costs by 2025 through this “strategic productivity initiative”. In Europe, Swiss-based companies like Novartis and Roche have announced substantial job cuts, while Bayer is reducing its workforce globally.  Bayer is laying off 1,816 employees worldwide, including 150 in Basel, Switzerland. A majority of these are management roles as the German drugmaker seeks to target € 500 million (US$ 557 million) in cost savings in 2024 and € 2 billion (US$ 2.23 billion) in 2026. Japanese drugmaker Takeda plans to eliminate 1,155 positions, including 324 jobs in San Diego and 641 in Massachusetts. Takeda is also winding down production and R&D operations in Austria, resulting in 190 job losses. Starting next month, Genentech, a Roche subsidiary, will lay off 93 employees in San Francisco. Earlier this year, Genentech trimmed roughly 3 percent of its workforce across several departments, impacting 436 employees. Roche also laid off around 340 employees in its product development team. Novartis has been undergoing a significant restructuring exercise since 2022, when it announced 8,000 job cuts in its global workforce. This year, it announced an additional 770 job cuts in its product development organization, separate from the previous reductions. Once again, it was workforces in Switzerland (440 job cuts) and US (269 job cuts) that bore the brunt. Tylenol and Band-Aid maker Kenvue, which spun off from J&J last year, announced plans to cut 920 jobs, representing about 4 percent of its global workforce. Additionally, the company will lay off 51 employees in New Jersey and 84 in California. These layoffs are part of Kenvue’s efforts to adjust its cost structure and become more competitive.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available)  Perrigo, Emergent Bio, Catalent, BioMarin trim workforces amid strategic shifts Several mid-size companies too are under tremendous cost pressures, with some of them feeling the need to reinvent themselves for the future. In February this year, Perrigo had embarked on ‘Project Energize’, a three-year initiative aimed at boosting organizational agility and achieving long-term success. As part of this project, Perrigo is cutting costs and laying off 6 percent of its staff, which translates into nearly 550 employees. CDMO-turned-biopharma Emergent BioSolutions plans to reduce its workforce by about 300 employees. The Maryland-based multinational is closing its Baltimore-Bayview drug substance manufacturing facility and its Rockville drug product facility in the state. Rare disease biotech BioMarin laid off 395 employees globally, about 12 percent of its workforce, as part of “organizational redesign efforts” to prioritize its new strategy with its hemophilia A gene therapy Roctavian and to preserve cash. Drug-delivery specialist Catalent has also been significantly impacted by restructuring efforts ever since it announced 1,100 layoffs in December. It had then attributed its fall in revenue to declining Covid-related sales, but had also noted that future GLP-1 manufacturing revenues could help stabilize its finances. True enough — it subsequently announced that it is in the process of being acquired by Novo Nordisk’s parent company for US$ 16.5 billion. However, Catalent reported reducing its headcount by an additional 300 in the fourth quarter of 2023.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available)  Pfizer job cuts continue to trickle in; Lykos, Lyra downsize after pipeline setbacks Clinical trial failures and financial constraints have also played a significant role in this year’s wave of layoffs. At Pfizer, job cuts continued to trickle in, with some estimates putting the number at 1,500 employees in 2024. These include 285 at its vaccine R&D site in New York, and 52 in San Francisco. The Comirnaty maker also pulled the plug on a long-anticipated, near-complete Seagen drug manufacturing plant in Everett, Washington. About 120 employees at the site were let go.  It has been a tumultuous time for Lykos Therapeutics, following the US Food and Drug Administration’s rejection of its MDMA-assisted therapy for post-traumatic stress disorder. Lykos announced laying off 75 percent of its staff (i.e. 75 employees). Its founder, who had spent 38 years working on the therapy, left the company and so did its CEO. However, Lykos has not given up and has roped in a Janssen veteran as senior medical advisor to get the therapy past the finish line. Similarly, Lyra Therapeutics is laying off 75 percent of its workforce (i.e. 87 employees) following disappointing late-stage results for its implant to treat chronic rhino-sinusitis. The retrenchments include its chief technology officer.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available)  Our view Technology, regulatory and pricing pressures are shaping strategies of pharmaceutical companies. The drive to do more with less could accelerate the adoption of artificial intelligence, machine learning, and automation in drug discovery and development processes. The employment landscape is certainly evolving. We foresee significant changes in the skills required for pharmaceutical and biotech careers, with a growing emphasis on data science and computational biology.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 560

    https://www.pharmacompass.com/radio-compass-blog/bms-bayer-takeda-pfizer-downsize-to-combat-cost-pressures-meet-restructuring-plans

    #PharmaFlow by PHARMACOMPASS
    19 Sep 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Applying Agile methodologies in CDMOs
    Applying Agile methodologies in CDMOs

    14 May 2021

    // EXPRESS PHARMA

    https://www.expresspharma.in/applying-agile-methodologies-in-cdmos/

    EXPRESS PHARMA
    14 May 2021
    Share Share
    External Communication - Covid-19
    External Communication - Covid-19

    15 Mar 2021

    // PRESS RELEASE

    http://www.uquifa.com/en/news/267-external-communication-covic-19

    PRESS RELEASE
    15 Mar 2021
    Share Share
    Esteve and Uquifa are involved in the manufacture of Remdesivir
    Esteve and Uquifa are involved in the manufacture of Remdesivir

    24 Jul 2020

    // ELNACIONAL

    https://www.elnacional.cat/ca/salut/esteve-uquifa-participen-fabricacio-remdesivir-gilead_525204_102.html

    ELNACIONAL
    24 Jul 2020
    Share Share
    Union Quimico Farmaceutica on FDA Import Alert List
    Union Quimico Farmaceutica on FDA Import Alert List

    22 Jul 2020

    // FDA

    https://www.accessdata.fda.gov/cms_ia/importalert_189.html

    FDA
    22 Jul 2020
    Share Share
    UQUIFA-Union Farmaceutica S.A. on Health Canada Inspection List
    UQUIFA-Union Farmaceutica S.A. on Health Canada Inspection List

    13 May 2020

    // HEALTH CANADA

    https://www.pharmacompass.com/pdf/news/uquifa-union-farmaceutica-sa-on-health-canada-inspection-list-1589346775.pdf

    HEALTH CANADA
    13 May 2020
    Share Share
    Vivimed's Uquifa expects Euro 200 mn revenues in 4 yrs
    Vivimed's Uquifa expects Euro 200 mn revenues in 4 yrs

    23 Mar 2020

    // BUSINESS-STANDARD

    https://www.business-standard.com/article/pti-stories/vivimed-s-uquifa-expects-euro-200-mn-revenues-in-4-yrs-118080100629_1.html

    BUSINESS-STANDARD
    23 Mar 2020
    Share Share

    Services

    Upload your portfolio for free, ask us

    Analytical

    Click here to discover the service providers for Analytical

    API Manufacturing

    Click here to discover the service providers for API Manufacturing

    API & Drug Product Development

    Click here to discover the service providers for API & Drug Product Development

    Sales, Marketing, Registration

    Click here to discover the service providers for Sales, Marketing, Registration

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact UQUIFA and get a quotation

    UQUIFA is a supplier offers 106 products (APIs, Excipients or Intermediates).

    Find a price of Ciprofloxacin bulk with DMF, CEP, JDMF offered by UQUIFA

    Find a price of Clindamycin Phosphate bulk with DMF, CEP, JDMF offered by UQUIFA

    Find a price of Ketoconazole bulk with DMF, CEP, JDMF offered by UQUIFA

    Find a price of Lansoprazole bulk with DMF, CEP, JDMF offered by UQUIFA

    Find a price of Metformin bulk with DMF, CEP, JDMF offered by UQUIFA

    Find a price of Omeprazole bulk with CEP, JDMF offered by UQUIFA

    Find a price of Aciclovir bulk with DMF, CEP offered by UQUIFA

    Find a price of Allopurinol bulk with DMF, CEP offered by UQUIFA

    Find a price of Cimetidine bulk with DMF, CEP offered by UQUIFA

    Find a price of Doxylamine Succinate bulk with DMF, CEP offered by UQUIFA

    Find a price of Famotidine bulk with DMF, CEP offered by UQUIFA

    Find a price of Nimodipine bulk with DMF, CEP offered by UQUIFA

    Find a price of Pantoprazole Sodium bulk with DMF, CEP offered by UQUIFA

    Find a price of Quetiapine Hemifumarate bulk with DMF, CEP offered by UQUIFA

    Find a price of Sitagliptin Phosphate bulk with DMF, CEP offered by UQUIFA

    Find a price of Solifenacin Succinate bulk with DMF, CEP offered by UQUIFA

    Find a price of Terbinafine Hydrochloride bulk with DMF, JDMF offered by UQUIFA

    Find a price of Tolterodine Tartrate bulk with DMF, CEP offered by UQUIFA

    Find a price of Carisoprodol bulk with DMF offered by UQUIFA

    Find a price of Esomeprazole Magnesium bulk with DMF offered by UQUIFA

    Find a price of Esomeprazole Sodium bulk with CEP offered by UQUIFA

    Find a price of Lamotrigine bulk with CEP offered by UQUIFA

    Find a price of Minocycline Hydrochloride bulk with CEP offered by UQUIFA

    Find a price of Quetiapine Hemifumarate bulk with CEP offered by UQUIFA

    Find a price of Ranitidine Hydrochloride bulk with DMF offered by UQUIFA

    Find a price of Zolpidem Tartrate bulk with CEP offered by UQUIFA

    Find a price of Albendazole bulk with DMF offered by UQUIFA

    Find a price of Bicalutamide bulk with DMF offered by UQUIFA

    Find a price of Cinacalcet Hydrochloride bulk with DMF offered by UQUIFA

    Find a price of Ciprofloxacin Hydrochloride bulk with DMF offered by UQUIFA

    Find a price of Clindamycin Phosphate bulk offered by UQUIFA

    Find a price of Cyclopentolate Hydrochloride bulk with DMF offered by UQUIFA

    Find a price of Duloxetine Hydrochloride bulk with CEP offered by UQUIFA

    Find a price of Ketorolac Trometamol bulk offered by UQUIFA

    Find a price of Levofloxacin bulk with DMF offered by UQUIFA

    Find a price of Mivacurium Chloride bulk with DMF offered by UQUIFA

    Find a price of Nitrendipine bulk with CEP offered by UQUIFA

    Find a price of Omeprazole bulk with DMF offered by UQUIFA

    Find a price of Omeprazole Sodium bulk with JDMF offered by UQUIFA

    Find a price of Pyrantel Pamoate bulk with DMF offered by UQUIFA

    Find a price of Pyrantel Tartrate bulk with DMF offered by UQUIFA

    Find a price of Ranolazine bulk with DMF offered by UQUIFA

    Find a price of Rivaroxaban bulk with DMF offered by UQUIFA

    Find a price of Telmisartan bulk with DMF offered by UQUIFA

    Find a price of Tropicamide bulk with DMF offered by UQUIFA

    Find a price of 2-Isopropyl-4-Methylaminomethyl-Thiazole bulk offered by UQUIFA

    Find a price of Bupropion Hydrochloride bulk offered by UQUIFA

    Find a price of Carisoprodol bulk offered by UQUIFA

    Find a price of Cilostazol bulk offered by UQUIFA

    Find a price of Ciprofloxacin Hydrochloride bulk offered by UQUIFA

    Find a price of Clindamycin Hydrochloride bulk offered by UQUIFA

    Find a price of Doxylamine Succinate bulk offered by UQUIFA

    Find a price of Duloxetine Hydrochloride bulk offered by UQUIFA

    Find a price of Fluoxetine Hydrochloride bulk offered by UQUIFA

    Find a price of Gatifloxacin bulk offered by UQUIFA

    Find a price of Iopamidol bulk offered by UQUIFA

    Find a price of L-VALINE bulk offered by UQUIFA

    Find a price of Labetalol Hydrochloride bulk offered by UQUIFA

    Find a price of Linezolid bulk offered by UQUIFA

    Find a price of Meloxicam bulk offered by UQUIFA

    Find a price of Memantine Hydrochloride bulk offered by UQUIFA

    Find a price of Modafinil bulk offered by UQUIFA

    Find a price of Nelfinavir Mesylate bulk offered by UQUIFA

    Find a price of Omeprazole bulk offered by UQUIFA

    Find a price of Omeprazole Magnesium bulk offered by UQUIFA

    Find a price of Rabeprazole bulk offered by UQUIFA

    Find a price of Ranitidine bulk offered by UQUIFA

    Find a price of Ranitidine Hydrochloride bulk offered by UQUIFA

    Find a price of Risedronate Sodium bulk offered by UQUIFA

    Find a price of Valacyclovir Hydrochloride bulk offered by UQUIFA

    Find a price of Venlafaxine Hydrochloride bulk offered by UQUIFA

    Find a price of Zolpidem Tartrate bulk offered by UQUIFA

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES OF CIMETIDINE USP IN BARCELONA, SPAIN. bulk offered by UQUIFA

    Find a price of FLUOROSULFONYLETHANONE bulk offered by UQUIFA

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BARCELONA, SPAIN. bulk offered by UQUIFA

    Find a price of 2,4-WING ACTIVE ESTER bulk offered by UQUIFA

    Find a price of Apixaban bulk offered by UQUIFA

    Find a price of Benzydamine Hydrochloride bulk offered by UQUIFA

    Find a price of Bilastine bulk offered by UQUIFA

    Find a price of Brexpiprazole bulk offered by UQUIFA

    Find a price of Brivaracetam bulk offered by UQUIFA

    Find a price of Cariprazine Hydrochloride bulk offered by UQUIFA

    Find a price of Crisaborole bulk offered by UQUIFA

    Find a price of Dabigatran Etexilate Mesylate bulk offered by UQUIFA

    Find a price of Edoxaban Tosylate bulk offered by UQUIFA

    Find a price of Elagolix Sodium bulk offered by UQUIFA

    Find a price of Esketamine Hydrochloride bulk offered by UQUIFA

    Find a price of Etofenamate bulk offered by UQUIFA

    Find a price of Hydroxychloroquine Sulphate bulk offered by UQUIFA

    Find a price of Hydroxyzine Dihydrochloride bulk offered by UQUIFA

    Find a price of Hydroxyzine Pamoate bulk offered by UQUIFA

    Find a price of Ketamine Hydrochloride bulk offered by UQUIFA

    Find a price of Lasmiditan bulk offered by UQUIFA

    Find a price of Lesinurad bulk offered by UQUIFA

    Find a price of Levofloxacin Hemihydrate bulk offered by UQUIFA

    Find a price of Mirabegron bulk offered by UQUIFA

    Find a price of Morantel Tartrate bulk offered by UQUIFA

    Find a price of Oxantel Pamoate bulk offered by UQUIFA

    Find a price of Oxibendazole bulk offered by UQUIFA

    Find a price of Pethidine Hydrochloride bulk offered by UQUIFA

    Find a price of Pimavanserin Tartrate bulk offered by UQUIFA

    Find a price of Propofol bulk offered by UQUIFA

    Find a price of Ricobendazole bulk offered by UQUIFA

    Find a price of Robenidine HCl bulk offered by UQUIFA

    Find a price of Tavaborole bulk offered by UQUIFA

    Find a price of Ursodeoxycholic Acid bulk offered by UQUIFA

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search